SEL-212
Selecta Biosciences
[]
$selb selecta biosciences announces presentation of data from phase 3 dissolve program of sel-212 in chronic refractory gout during late-breaking session at the eular 2023 european congress of rheumatology #clinicaltrial#trading 
Stay ahead of the market with ultra-fast stock news updates. 
FREE with 15 sec delay. Upgrade to Gold for even faster news & exclusive features @ https://t.co/LViEqnfZ7i